+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report



Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report



Intervirology 55(4): 306-310



We report a case in which sustained viral response was achieved after switching treatment from pegylated interferon (PEG-IFN) α-2b to α-2a and ribavirin (RBV) in patients with recurrence of hepatitis C virus (HCV) infection after living donor liver transplantation. The patient was a 62-year-old man with liver cirrhosis due to HCV genotype 1b infection. The patient had 8 amino acid (aa) substitutions in the interferon sensitivity-determining region, and had substitutions for mutant and wild-type at aa70 and aa91, respectively, in the core region. The patient had minor genotype (GG) IL28B single nucleotide polymorphisms (rs8099917). He had initially received interferon α-2b and RBV for 2 years, and later developed hepatocellular carcinoma (HCC). After surgical resection of HCC, he subsequently received PEG-IFN α-2b and RBV for 1.5 years, without undetectable viremia during the treatment course. Due to recurrence of HCC, the patient received a living donor liver transplantation. Later on, hepatitis C relapsed. For the management of relapse, he received another course of PEG-IFN α-2b and RBV. However, breakthrough viremia occurred. PEG-IFN was thus switched from α-2b to α-2a and RBV for another 17 months. The patient eventually achieved a sustained viral response.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051331877

Download citation: RISBibTeXText

PMID: 21865660

DOI: 10.1159/000328661


Related references

Su1074 Meta-Analysis: Sustained Virologic Response (Svr) in Patients With Infection With Hepatitis C Virus Genotype 5 (Hcv-5) Versus Genotype 1 (Hcv-1) and Hcv Genotype 2/3 (Hcv -2/3) Treated With Interferon (Ifn) or Pegylated Interferon and Ribavirin (Peg Ifn+Rbv). Gastroenterology 146(5): S-981-S-982, 2014

High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation. Hepatology International 9(1): 76-83, 2015

Meta-Analysis: Sustained Virologic Response (Svr) in Asian Patients With Infection With Hepatitis C Virus Genotype 6 (Hcv-6) Versus Genotype 1 (Hcv-1) Treated With Pegylated Interferon and Ribavirin (Peg Ifn+Rbv) for 48 Weeks. Gastroenterology 146(5): S-921-S-922, 2014

W1015 Analysis of Sustained Virological Response to Pegylated Interferon & Ribavirin Treatment in Compensated Cirrhosis Due to Hepatitis C Virus, Genotype 3 Infection. Gastroenterology 134(4): A-832, 2008

Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation. Hepatology Research 41(12): 1137-1144, 2011

Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report. Journal of Medical Case Reports 8: 257, 2014

Predictability of sustained virological response to pegylated interferon alpha-2b Plus ribavirin therapy by week-8 viral response in HIV-positive patients with chronic hepatitis C virus infection. Current HIV Research 7(4): 447-455, 2009

Predictability of Sustained Virological Response to Pegylated Interferon Alpha-2b Plus Ribavirin Therapy by Week-8 Viral Response in Hivpositive Patients with Chronic Hepatitis C Virus Infection. Current Hiv Research 7(4): 447-455, 2009

Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin. Zhonghua Gan Zang Bing Za Zhi 24(3): 175-180, 2016

Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin. Scandinavian Journal of Gastroenterology 45(2): 250-255, 2010

Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients. Hepatology International 9(3): 431-437, 2015

Severe liver injury associated with simeprevir plus pegylated interferon/ribavirin therapy in a patient with treatment-naïve genotype 1b hepatitis C virus: a case report. Clinical Journal of Gastroenterology 7(5): 465-470, 2014

Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis. Digestion 79(1): 36-39, 2009

Su1073 Sustained Virological Response (Svr) to Standard Interferon (Ifn) or Pegylated Interferon (Peg Ifn) and Ribavirin (Rbv) in Patients With Hepatitis C Virus Genotype 5 (Hcv-5): Results of a Meta-Analysis of 423 Patients From 10 Individual Studies. Gastroenterology 146(5): S-981, 2014

Treatment of chronic hepatitis C virus infection with pegylated interferon and ribavirin in cirrhotic patients awaiting liver transplantation. Transplantation Proceedings 40(6): 1918-1920, 2008